type 2 diabetes
Our results suggest that PPARG variation may underlie response to TZD therapy in women at risk for type 2 diabetes.
Our results suggest that <span class="gene" id="16249460-12-25-30">PPARG</span> variation may underlie response to TZD therapy in women at risk for <span class="disease" id="16249460-12-99-114">type 2 diabetes</span>.